Find your next quality investment with Simply Wall St’s easy and powerful screener, trusted by over 7 million individual investors worldwide.
Recent performance snapshot
Novo Nordisk (NYSE:NVO) has drawn investor attention after a mixed stretch for the stock, with a gain of 2.7% over the past day contrasted with a decline of 6.5% over the past month.
See our latest analysis for Novo Nordisk.
Zooming out, Novo Nordisk’s recent bounce comes after a softer patch, with the share price up over the past quarter but down year to date, while the 1 year total shareholder return is also lower. This suggests momentum has cooled compared with earlier periods.
If you are comparing Novo Nordisk with other healthcare opportunities, this is a good moment to see what else the market is pricing into 40 healthcare AI stocks
With the stock down 16.1% year to date and the latest close at US$43.96, the big question now is whether Novo Nordisk’s current valuation still leaves upside on the table, or if the market is already pricing in future growth.
Most Popular Narrative: 53.7% Undervalued
According to the most followed narrative on Simply Wall St, Novo Nordisk’s fair value of $95 sits well above the latest close of $43.96, pointing to a wide valuation gap.
“Valuation: We estimate fair value at ~$95 per ADR (base-case range $90–$100), reflecting a more competitive, more price-sensitive regime than the peak GLP-1 narrative, but also acknowledging the durability of the franchise and the expanding product/indication set.”
Curious what kind of revenue profile, margins, and future earnings power have to line up to support that figure? The narrative stitches those assumptions together into a single, punchy fair value story that is very different from what the current share price implies.
Result: Fair Value of $95 (UNDERVALUED)
Have a read of the narrative in full and understand what’s behind the forecasts.
However, this depends on key risks, including sustained pricing pressure and stronger GLP-1 competition, which could compress margins and challenge the fair value case.
Find out about the key risks to this Novo Nordisk narrative.
Next Steps
With sentiment split between concern over risks and optimism about rewards, this is the moment to look at the numbers yourself and decide how the trade off stacks up, starting with the 3 key rewards and 3 important warning signs
Looking for more investment ideas?
If Novo Nordisk has you thinking more carefully about price, risk, and quality, do not stop here. Broaden your watchlist with focused stock shortlists.